key: cord-0855451-zzclhtoi
authors: Riva, Nilo; Russo, Tommaso; Falzone, Yuri Matteo; Strollo, Marta; Amadio, Stefano; Del Carro, Ubaldo; Locatelli, Massimo; Filippi, Massimo; Fazio, Raffaella
title: Post-infectious Guillain–Barré syndrome related to SARS-CoV-2 infection: a case report
date: 2020-05-26
journal: J Neurol
DOI: 10.1007/s00415-020-09907-z
sha: c367ea2bad2c9ee1c25e67d963c9f983e39a27e5
doc_id: 855451
cord_uid: zzclhtoi

nan

mild ageusia. At admission, vital signs and general examination were normal. Neurological examination disclosed moderate proximal muscle weakness (Medical Research Council Grade 3-4/5) and severe vibratory sensation and proprioception deficit at lower limbs. Deep tendon reflexes were absent. Cell blood count, C-reactive protein, creatine phosphokinase, arterial blood gases, renal and hepatic function tests were normal. Anti-ganglioside antibodies tested negative. Serum levels of interleukin-6 [93.1 pg/ml; (reference 0-7 pg/ml)], ferritin [1040 ng/ml (30-400 ng/ml)], lactic dehydrogenase [281 U/l (125-220 U/l)] and fibrinogen [525 mg/dl (150-400 mg/dl)] were elevated. Chest CT scan showed bilateral ground-glass opacities, consistent with COVID-19 pneumonia. Two nasal swabs tested negative for SARS-CoV-2. Cervical spine MRI ruled out lesions of the cervical cord [2] . CSF testing (day 3) showed normal cell count and protein levels. Polymerase-chain reaction for EBV, CMV, VZV, HSV 1-2, HIV and SARS-CoV2 on CSF tested negative. Nerve conduction studies (day 5) showed reduced conduction velocities, reduced sensory action potential and compound motor action potential (cMAP) amplitudes with sural nerve sparing and abnormal temporal dispersion of peroneal nerves cMAP, indicating an acute inflammatory demyelinating polyneuropathy (Table 1 ) [3] . We started a 5-day course of intravenous immunoglobulin at 0.4 g/kg daily. A thorough serological analysis ruled out other causes of atypical pneumonia. As soon as available, SARS-CoV-2 IgG tested positive [DiaSorin LIAISON system: 81.2 AU/ ml (< 12 AU/ml)]. Muscle weakness worsened and rapidly spread distally and to thoracic and cranial nerves causing facial diplegia, hypophonia and dysarthria. The time from symptoms onset to nadir was 10 days, followed by a slow improvement; no ventilation or feeding tube support was required.

Few cases of GBS have already been reported in concomitance with SARS-CoV-2 infection [4] [5] [6] . While epidemiological data and radiological findings guided our Vita-Salute San Raffaele University, Milan, Italy presumptive diagnosis of SARS-CoV2, serological tests proved essential for its confirmation. Therefore, despite the negativity of two repeated nasal swabs, we were able to implement appropriate isolation precautions. The timing of the onset of neurological symptoms, together with the negativity of oropharyngeal swabs and the demonstration of a SARS-CoV2 IgG response, are all in support of a postinfective immune-mediated disease mechanism. Recent evidence suggests that although the immune response seems crucial to control and resolve the viral infection, an excessive, dysregulated inflammatory response may also be detrimental. Increased levels of IL-6, as detected in our patient, and other pro-inflammatory cytokines, referred to as "cytokine storm", are considered a hallmark of this aberrant reaction [7] . GBS has a recognized dysimmune pathogenesis, mediated by the antibody response. Therefore, we might speculate that also other neurological or extra-neurological SARS-CoV-2-related manifestations might share similar pathogenic mechanisms, suggesting tailored therapeutic approaches for subgroup of patients.

Funding The authors did not receive any compensation for the manuscript. 

Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan. China

Churg strauss syndrome presenting as acute neuropathy resembling Guillain Barre syndrome: case report

Diagnosis and management of Guillain-Barre syndrome in ten steps

Guillain-Barre syndrome associated with SARS-CoV-2 infection: causality or coincidence?

Guillain-Barre syndrome associated with SARS-CoV-2

Guillain-Barre syndrome following COVID-19: new infection, old complication?

Advances in COVID-19: the virus, the pathogenesis, and evidence-based control and therapeutic strategies

The authors declare that they have no conflict of interest.Ethical standard statement We have obtained the patient's informed consent and permission for the publishing of his information.